1 |
IL17F
| [2] Th17 cell differentiation Th17 cell differentiation, Inflammatory bowel disease | D11550
D11550
|
Bimekizumab
| [3] 46 46, 97, 271 |
2 |
IFNG
| [20] Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis | D04242
D04242
|
Fontolizumab
| [1] 46 46 |
3 |
IFNG
| [20] Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis | D11120
D11120
|
Emapalumab
| [3] 49 49, 65, 107 |
4 |
IFNGR1
| [14] Necroptosis Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | D00747
D00747
|
Interferon gamma-1b
| [7] 18 18, 65, 85, 228, 299, 301, 326 |
5 |
IFNGR2
| [13] Necroptosis Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Influenza A, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | D00747
D00747
|
Interferon gamma-1b
| [7] 18 18, 65, 85, 228, 299, 301, 326 |
6 |
IL1A
| [14] MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
7 |
IL1A
| [14] MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
8 |
IL1A
| [14] MAPK signaling pathway MAPK signaling pathway, Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis | D11253
D11253
|
Bermekimab
| [1] 51 51 |
9 |
IL1B
| [27] MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
10 |
IL1B
| [27] MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D06635
D06635
|
Rilonacept
| [4] 51 51, 106, 107, 266 |
11 |
IL1B
| [27] MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D09315
D09315
|
Canakinumab
| [10] 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
12 |
IL1B
| [27] MAPK signaling pathway MAPK signaling pathway, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D09911
D09911
|
Gevokizumab
| [4] 41 41, 50, 56, 269 |
13 |
IL2RG
| [9] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
14 |
IL4
| [9] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Inflammatory bowel disease | D03117
D03117
|
Binetrakin
| [1] 46 46 |
15 |
IL4R
| [6] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D10354
D10354
|
Dupilumab
| [5] 51 51, 97, 98, 160, 162 |
16 |
IL5
| [6] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease | D04923
D04923
|
Mepolizumab
| [4] 44 44, 45, 98, 162 |
17 |
IL5
| [6] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Inflammatory bowel disease | D08985
D08985
|
Reslizumab
| [2] 44 44, 98 |
18 |
IL6
| [27] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
19 |
IL6
| [27] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| [5] 28 28, 51, 85, 227, 331 |
20 |
IL6
| [27] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D09669
D09669
|
Siltuximab
| [2] 28 28, 331 |
21 |
IL6
| [27] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D10080
D10080
|
Sirukumab
| [2] 41 41, 46 |
22 |
IL6
| [27] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Lipid and atherosclerosis | D12487
D12487
|
Olokizumab
| [2] 46 46, 96 |
23 |
IL10
| [13] Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Inflammatory bowel disease, Systemic lupus erythematosus | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
24 |
IL12A
| [16] Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Pathways in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
25 |
IL12B
| [16] Toll-like receptor signaling pathway Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
26 |
IL13
| [4] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D08857
D08857
|
Anrukinzumab
| [1] 97 97 |
27 |
IL13
| [4] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D09633
D09633
|
Lebrikizumab
| [1] 85 85 |
28 |
IL13
| [4] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D09979
D09979
|
Tralokinumab
| [2] 85 85, 97 |
29 |
IL17A
| [3] Th17 cell differentiation Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis | D09967
D09967
|
Secukinumab
| [8] 13 13, 37, 41, 46, 107, 160, 269, 271 |
30 |
IL17A
| [3] Th17 cell differentiation Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis | D10071
D10071
|
Ixekizumab
| [8] 36 36, 37, 46, 107, 160, 162, 269, 271 |
31 |
IL17A
| [3] Th17 cell differentiation Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis | D11127
D11127
|
Tibulizumab
| [1] 53 53 |
32 |
IL17A
| [3] Th17 cell differentiation Th17 cell differentiation, Inflammatory bowel disease, Rheumatoid arthritis | D11550
D11550
|
Bimekizumab
| [3] 46 46, 97, 271 |
33 |
NFKB1
| [43] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D01146
D01146
|
Iguratimod
| [5] 46 46, 51, 53, 271, 300 |
34 |
IL22
| [3] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | D11953
D11953
|
Efmarodocokin alfa
| [2] 96 96, 97 |
35 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
36 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10400
D10400
|
Tildrakizumab
| [2] 162 162, 271 |
37 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10438
D10438
|
Guselkumab
| [5] 37 37, 41, 51, 96, 97 |
38 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10912
D10912
|
Brazikumab
| [2] 96 96, 97 |
39 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11052
D11052
|
Risankizumab
| [4] 37 37, 96, 97, 271 |
40 |
IL23A
| [7] JAK-STAT signaling pathway JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11123
D11123
|
Mirikizumab
| [3] 37 37, 96, 97 |
41 |
RELA
| [43] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Lipid and atherosclerosis | D12181
D12181
|
Edasalonexent
| [1] 113 113 |
42 |
TGFB1
| [17] MAPK signaling pathway MAPK signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09620
D09620
|
Fresolimumab
| [3] 51 51, 85, 222 |
43 |
TGFB2
| [14] MAPK signaling pathway MAPK signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09620
D09620
|
Fresolimumab
| [3] 51 51, 85, 222 |
44 |
TGFB3
| [11] MAPK signaling pathway MAPK signaling pathway, TGF-beta signaling pathway, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, Renal cell carcinoma, Pancreatic cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09620
D09620
|
Fresolimumab
| [3] 51 51, 85, 222 |
45 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D00742
D00742
|
Etanercept
| [16] 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
46 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
47 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| [11] 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
48 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D02597
D02597
|
Adalimumab
| [17] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
49 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
50 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
51 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
52 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D04687
D04687
|
Lenalidomide
| [8] 16 16, 26, 28, 34, 49, 284, 300, 331 |
53 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D05393
D05393
|
Pegsunercept
| [1] 46 46 |
54 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| [5] 28 28, 51, 85, 227, 331 |
55 |
TNF
| [36] MAPK signaling pathway MAPK signaling pathway, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Influenza A, Proteoglycans in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Lipid and atherosclerosis | D09944
D09944
|
Ozoralizumab
| [1] 46 46 |